Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Treatment resistance and clozapine
Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Clozapine-associated medical emergency
Fever or sore throat with neutropenia risk, chest pain or persistent tachycardia suggesting myocarditis, severe constipation with pain or vomiting, seizure, collapse, marked sedation or toxicity during infection needs immediate action.
Action: Contact the clozapine monitoring and specialist team urgently, obtain observations, ECG and syndrome-specific blood tests, and follow the current product and monitoring-service hold rules. Treat sepsis, myocarditis, bowel obstruction, seizure or toxicity as an emergency and do not improvise restarting after interruption.
Purpose and principles
Confirm genuine treatment-resistant schizophrenia after two adequate sequential antipsychotic trials, offer clozapine without avoidable delay, maintain psychological and social care, and prevent haematological, cardiac, gastrointestinal, metabolic and concentration-related harm through registered phased monitoring.
Treatment resistance is a conclusion after verification, not a synonym for continuing symptoms. Reconstruct each antipsychotic trial from prescriptions, dispensing, patient account, collateral and, where useful, plasma concentrations. Record target symptoms, actual dose, duration, adherence, response and adverse effects. Review affective or neurological diagnoses, substance use, medicine interactions, trauma, cognitive disability and environmental stress. CBT and family intervention should remain available, but their uptake or failure is not part of the pharmacological treatment-resistance criterion and must not delay a clozapine offer after two adequate antipsychotic trials.
NICE recommends offering clozapine when schizophrenia has not responded adequately to sequential adequate doses of at least two different antipsychotics, one a non-clozapine second-generation drug. Discuss its distinctive evidence and burdens: regular blood monitoring, titration visits, sedation, hypersalivation, constipation, weight and metabolic effects, seizure risk and potentially serious neutropenia or myocarditis. Explore practical access, blood-test fear, previous information and support needs. A shared decision includes the consequences of not offering an effective treatment.
Indications, selection and cautions
Verified treatment resistance
Persistent disabling schizophrenia symptoms remain after two different adequate sequential antipsychotic trials with sufficient adherence, dose and duration documented.
Pseudo-resistance
Poor medicine exposure, intolerable adverse effects, substance use, inaccurate diagnosis or a pharmacokinetic interaction can explain apparent antipsychotic failure and requires correction.
Early myocarditis signal
Persistent tachycardia with chest symptoms, breathlessness, fatigue, fever or flu-like illness during early titration warrants urgent cardiac investigation.
Gastrointestinal hypomotility
Reduced bowel frequency, hard stool, distension, pain, nausea or vomiting during clozapine treatment can progress from constipation to life-threatening obstruction.
Concentration-related toxicity
Sedation, confusion, hypersalivation, myoclonus or seizure after infection, smoking cessation or interaction suggests increased exposure and needs urgent review.
Red flags requiring action
Fever, sore throat, mouth ulceration or other infection symptoms during clozapine treatment requires an urgent full blood count and monitoring-service advice.
Persistent resting tachycardia, chest pain, dyspnoea, unexplained fatigue or flu-like illness early in titration raises myocarditis and requires prompt cardiac assessment.
Two genuinely adequate failed trials support clozapine eligibility; gaps identify remediable pseudo-resistance but should be addressed within a time-limited plan.
Apply the Wim's Protocol baseline with the SmPC, monitoring service and local policy; results determine eligibility, titration speed and prevention, while a current acceptable blood result governs supply.
03Wim's Protocol phase review
Why
Apply the defined titration, stabilisation, early-maintenance, first-year and long-term physical monitoring checkpoints.
Interpretation and limitations
Each phase changes observation and investigation frequency; the framework supplements rather than replaces mandatory full-blood-count rules, product warnings and symptom-triggered emergency assessment.
04Mandatory blood-count surveillance
Why
Detect neutropenia through the current UK product and monitoring-service schedule.
Interpretation and limitations
Use the service's colour or action category and current official thresholds; infection symptoms still require urgent assessment between scheduled samples.
Treatment approach
01Resistance reviewVerify and offer clozapineFirst stepSchizophrenia symptoms remain disabling after two apparent antipsychotic trials.+
1Review diagnosis, dose, duration, actual adherence, adverse effects, substances, interactions, physical illness and psychological treatment access.
2Document whether two sequential adequate trials, including a non-clozapine second-generation medicine, have genuinely failed.
3Offer clozapine with balanced benefit-harm information and practical support, avoiding repeated ineffective switching when eligibility is established.
02Clozapine initiationRegister, baseline and titrateThe person gives informed agreement and specialist assessment confirms clozapine suitability.+
1Register with the monitoring service and complete the Wim's Protocol blood, cardiac, metabolic, bowel, seizure, smoking, examination and interaction baseline.
Regimens, contraindications and interactions
The NICE-offered antipsychotic for verified treatment-resistant schizophrenia after two adequate sequential non-clozapine trials have not produced sufficient response.
Clozapine oral
Give 12.5 mg once or twice on day one, then 25 mg once or twice on day two if tolerated; increase by 25 mg to 50 mg daily to no more than 300 mg daily within two to three weeks, then by 50 mg to 100 mg at half-weekly or preferably weekly intervals toward the usual 200 mg to 450 mg daily range.
Mandatory registered blood monitoring is required; also monitor myocarditis, severe constipation and ileus, seizures, aspiration, metabolic effects, orthostasis and interactions, especially infection and changes in tobacco smoking.
Complications, monitoring and follow-up
Complete mandatory full blood counts at the current product and UK monitoring-service frequency and act on the service result before dispensing; Wim's Protocol does not replace those supply rules.
During titration weeks one to four, follow Wim's Protocol for pulse, lying and standing blood pressure, oxygen saturation and temperature three to four hours after each non-night-time dose where feasible, plus weekly blood count and early myocarditis surveillance with ECG, CRP, troponin I and NT-proBNP where available.
During stabilisation weeks five to eight, continue weekly physiological observations and blood count, repeat CRP and high-sensitivity troponin, obtain the week-eight ECG and maintain weight, BMI and adverse-effect review.
During early maintenance weeks nine to eighteen, continue weekly blood count, four-weekly physiological observations and the week-twelve cardiometabolic checkpoint and clozapine concentration after titration when indicated.
During maintenance weeks eighteen to fifty-two, use the protocol's two-weekly blood count, four-weekly physiological observations and six- and nine-month cardiometabolic checkpoints alongside current service requirements.
Special situations
Delay has consequences
Repeated trials after clear eligibility can prolong distress, admission and social loss while denying the only established treatment for resistant schizophrenia.
Nicotine is not the inducer
Combustion products in tobacco smoke alter clozapine metabolism, so switching to nicotine replacement can still raise concentration.
Constipation can kill
Clozapine gastrointestinal hypomotility can progress silently, making routine bowel enquiry and early treatment essential rather than optional comfort care.
Infection changes exposure
Inflammation can suppress metabolism and increase clozapine concentration, while sedation and aspiration may further complicate pneumonia.
Blood levels answer questions
A concentration is most useful when linked to a specific uncertainty about exposure, response or toxicity and interpreted with timing and context.
Common pitfalls
01
Calling treatment resistant without reconstructing adherence, dose, duration and competing diagnoses.
02
Postponing clozapine through repeated non-clozapine switches after NICE eligibility is established.
03
Treating scheduled neutrophil monitoring as the only physical safety obligation.
04
Recording constipation as a routine adverse effect without prevention, bowel history or emergency advice.
05
Missing toxicity after smoking cessation, serious infection or a new metabolic inhibitor.
06
Restarting the previous full dose after a treatment gap instead of re-titrating under specialist advice.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
PsychiatryOriginal SBA
Clozapine eligibility
A man with confirmed schizophrenia has persistent distressing delusions despite two sequential adequate antipsychotic trials with verified adherence, including one non-clozapine second-generation medicine. What should be offered next?
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
RCPsych Wim's Protocol version 1.1Primary UK physical-health monitoring framework, published June 2026 and updated 2 July 2026, covering preparation through long-term maintenance.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·
Initiation takes place through a registered UK monitoring system. RCPsych Wim's Protocol version 1.1, published in June 2026 and updated on 2 July 2026, provides the primary UK physical-health framework alongside the current SmPC, mandatory monitoring-service rules and local policy. Its baseline includes full blood count, renal and liver tests, HbA1c, lipids, CRP, troponin I, NT-proBNP, ECG, physiological observations, examination, bowel pattern, GASS-C and cardiometabolic measures. Start with 12.5 mg once or twice on day one, then 25 mg once or twice on day two if tolerated, increasing gradually under specialist supervision.
Prevention and early recognition of toxicity are daily clinical work. Ask and record bowel frequency, abdominal symptoms, fluid intake and other constipating medicines; use a proactive bowel plan according to risk and local protocol. Fever, sore throat or infection symptoms trigger urgent haematological advice. Persistent resting tachycardia, chest pain, breathlessness or disproportionate fatigue requires myocarditis assessment. Review swallowing, aspiration, hypersalivation, nocturnal sedation, weight, glucose, lipids and seizures. Avoid abrupt withdrawal except where immediate safety requires it because rebound psychosis and cholinergic symptoms can occur.
Clozapine exposure changes with context. Tobacco smoke, rather than nicotine itself, induces metabolism; stopping smoking can increase concentrations and toxicity, including during smoke-free admission. Pneumonia and other serious inflammation can also raise exposure. Measure a trough concentration when response or toxicity is uncertain and when MHRA clinical triggers apply. If symptoms persist after an optimised, tolerated and adequately exposed course, recheck formulation and psychosocial care before augmentation. Define target, duration and stopping rule and avoid combinations that compound clozapine's adverse effects.
Key points
Before calling illness treatment resistant, review diagnosis, two sequential adequate antipsychotic trials, actual adherence, dose, duration, substances and physical illness; psychological care should be offered but failure of it is not a clozapine eligibility criterion.
Offer clozapine when schizophrenia has not responded adequately despite at least two different antipsychotics at adequate doses, including at least one non-clozapine second-generation drug.
Register the patient, prescriber and dispensing pathway with the relevant UK clozapine monitoring service and obtain the required acceptable blood result before supply.
Start low and use the June 2026 RCPsych Wim's Protocol physical-monitoring phases alongside the SmPC and local policy: baseline, titration weeks one to four, stabilisation weeks five to eight, early maintenance weeks nine to eighteen, maintenance weeks eighteen to fifty-two and review beyond one year.
Ask about bowel frequency and symptoms at every contact and prescribe active prevention when risk is present; severe constipation is an emergency, not a minor inconvenience.
Smoking cessation, serious infection and CYP interactions can raise clozapine concentrations, while starting smoking can lower them and reduce response.
Measure clozapine concentration when toxicity, poor response, non-adherence, infection, smoking change or important interaction makes exposure uncertain, alongside mandatory blood-count monitoring.
No bowel movement with increasing distension, severe abdominal pain, vomiting or reduced bowel sounds suggests ileus or obstruction and can be fatal.
New confusion, profound drowsiness, myoclonus or seizure may reflect high clozapine exposure, rapid titration, interaction, infection or smoking cessation.
A treatment gap longer than the product threshold invalidates the previous titration and creates severe hypotension or collapse risk if the full dose is simply resumed.
05Cardiac and inflammatory assessment
Why
Investigate persistent tachycardia, chest pain, dyspnoea, fever or disproportionate fatigue during titration.
Interpretation and limitations
ECG, biomarkers and imaging are selected through the specialist protocol; suspected myocarditis requires prompt cessation and cardiology assessment under product guidance.
06Clozapine plasma concentration
Why
Clarify toxicity, adherence, poor response, smoking change, infection or important pharmacokinetic interaction.
Interpretation and limitations
Interpret a correctly timed concentration with dose, smoking, symptoms and co-medication; it supplements rather than replaces clinical and neutrophil monitoring.
2
During weeks one to four use the protocol's titration schedule for physiological observations, weekly blood count, myocarditis testing, ECG, weight, BMI and GASS-C, adapted safely to setting.
3EscalationProgress through weeks five to eight stabilisation and the later maintenance checkpoints while teaching supporters the infection, cardiac, bowel and toxicity escalation route.
03Deterioration on clozapineSeparate relapse from altered exposureSymptoms worsen or toxicity emerges after prior response or during an intercurrent illness.+
1Check adherence, last dose, treatment interruption, smoking, caffeine, interacting medicines, constipation, infection and physiological observations.
2Obtain mandatory blood tests and a clozapine concentration or organ-specific assessment when the presentation indicates, without delaying emergency care.
3Adjust, hold, restart or augment only with the monitoring service and specialist prescriber, documenting target, safety plan and follow-up.
Complete the twelve-month multidisciplinary physical review; beyond one year retain monthly red-flag review, permitted monthly or suitable opted-in three-monthly blood counts, six-monthly cardiometabolic checks and annual systems examination and laboratory review.
Ask about bowel frequency, stool, pain, distension, nausea and vomiting at every relevant contact and maintain an explicit prevention and rescue plan.
Track weight, waist, blood pressure, glucose or HbA1c, lipids, smoking, activity, sexual health, hypersalivation and aspiration risk over long-term treatment.
Review dose and consider plasma concentration after infection, smoking change, important interaction, toxicity, unexplained relapse or suspected non-adherence.
After any interruption confirm the exact gap and follow specialist re-titration rules rather than resuming the previous maintenance dose.
If optimised clozapine is insufficient, confirm adherence, concentration, duration, diagnosis and psychosocial care before a time-limited monitored augmentation trial.